Tcr2 Therapeutics Probability of Future Stock Price Finishing Over 1.61
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Tcr2 |
Tcr2 Therapeutics Target Price Odds to finish over 1.61
The tendency of Tcr2 Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 1.61 or more in 90 days |
| 1.48 | 90 days | 1.61 | about 53.98 |
Based on a normal probability distribution, the odds of Tcr2 Therapeutics to move over $ 1.61 or more in 90 days from now is about 53.98 (This Tcr2 Therapeutics probability density function shows the probability of Tcr2 Stock to fall within a particular range of prices over 90 days) . Probability of Tcr2 Therapeutics price to stay between its current price of $ 1.48 and $ 1.61 at the end of the 90-day period is about 23.35 .
Given the investment horizon of 90 days Tcr2 Therapeutics has a beta of -1.7. This usually implies as returns on its benchmark rise, returns on holding Tcr2 Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Tcr2 Therapeutics is expected to outperform its benchmark. Additionally Tcr2 Therapeutics has an alpha of 0.5733, implying that it can generate a 0.57 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Tcr2 Therapeutics Price Density |
| Price |
Predictive Modules for Tcr2 Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tcr2 Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tcr2 Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tcr2 Therapeutics is not an exception. The market had few large corrections towards the Tcr2 Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tcr2 Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tcr2 Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.57 | |
β | Beta against Dow Jones | -1.7 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | 0.05 |
Tcr2 Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tcr2 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tcr2 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tcr2 Therapeutics is not yet fully synchronised with the market data | |
| Tcr2 Therapeutics may become a speculative penny stock | |
| Tcr2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (151.82 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tcr2 Therapeutics currently holds about 175.99 M in cash with (101.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Tcr2 Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tcr2 Stock often depends not only on the future outlook of the current and potential Tcr2 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tcr2 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.6 M | |
| Cash And Short Term Investments | 149.2 M |
Tcr2 Therapeutics Technical Analysis
Tcr2 Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Tcr2 Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Tcr2 Therapeutics. In general, you should focus on analyzing Tcr2 Stock price patterns and their correlations with different microeconomic environments and drivers.
Tcr2 Therapeutics Predictive Forecast Models
Tcr2 Therapeutics' time-series forecasting models is one of many Tcr2 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Tcr2 Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Tcr2 Therapeutics
Checking the ongoing alerts about Tcr2 Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Tcr2 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Tcr2 Therapeutics is not yet fully synchronised with the market data | |
| Tcr2 Therapeutics may become a speculative penny stock | |
| Tcr2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (151.82 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tcr2 Therapeutics currently holds about 175.99 M in cash with (101.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |